WO1997019701A3 - Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates - Google Patents

Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates Download PDF

Info

Publication number
WO1997019701A3
WO1997019701A3 PCT/CA1996/000799 CA9600799W WO9719701A3 WO 1997019701 A3 WO1997019701 A3 WO 1997019701A3 CA 9600799 W CA9600799 W CA 9600799W WO 9719701 A3 WO9719701 A3 WO 9719701A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
antithrombin iii
glycosaminoglycan
heparin cofactor
heparin
Prior art date
Application number
PCT/CA1996/000799
Other languages
French (fr)
Other versions
WO1997019701A2 (en
Inventor
Leslie Berry
Maureen Andrew
Original Assignee
Hamilton Civic Hospitals Res
Leslie Berry
Maureen Andrew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Civic Hospitals Res, Leslie Berry, Maureen Andrew filed Critical Hamilton Civic Hospitals Res
Priority to AU76883/96A priority Critical patent/AU7688396A/en
Priority to JP52003397A priority patent/JP4166275B2/en
Priority to DE69636813T priority patent/DE69636813T2/en
Priority to EP96939779A priority patent/EP0863768B1/en
Priority to CA2237159A priority patent/CA2237159C/en
Publication of WO1997019701A2 publication Critical patent/WO1997019701A2/en
Publication of WO1997019701A3 publication Critical patent/WO1997019701A3/en
Priority to US10/268,084 priority patent/US20030113314A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome and on surfaces in contact with blood are also described.
PCT/CA1996/000799 1995-11-30 1996-11-29 Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates WO1997019701A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU76883/96A AU7688396A (en) 1995-11-30 1996-11-29 Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
JP52003397A JP4166275B2 (en) 1995-11-30 1996-11-29 Glycosaminoglycan-antithrombin III / heparin cofactor II conjugate
DE69636813T DE69636813T2 (en) 1995-11-30 1996-11-29 Heparin proteins covalent conjugates containing an alpha carbonyl amine and methods for their production
EP96939779A EP0863768B1 (en) 1995-11-30 1996-11-29 Covalent heparin-protein conjugates comprising an alpha-carbonyl amine bond and methods of obtaining them
CA2237159A CA2237159C (en) 1995-11-30 1996-11-29 Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
US10/268,084 US20030113314A1 (en) 1995-11-30 2002-10-10 Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/564,976 US6562781B1 (en) 1995-11-30 1995-11-30 Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US08/564,976 1995-11-30

Publications (2)

Publication Number Publication Date
WO1997019701A2 WO1997019701A2 (en) 1997-06-05
WO1997019701A3 true WO1997019701A3 (en) 1997-08-28

Family

ID=24256690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1996/000799 WO1997019701A2 (en) 1995-11-30 1996-11-29 Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates

Country Status (8)

Country Link
US (2) US6562781B1 (en)
EP (1) EP0863768B1 (en)
JP (1) JP4166275B2 (en)
AT (1) ATE350066T1 (en)
AU (1) AU7688396A (en)
CA (1) CA2237159C (en)
DE (1) DE69636813T2 (en)
WO (1) WO1997019701A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405905B (en) * 1997-03-25 1999-12-27 Immuno Ag NEW USE OF ANTITHROMBIN III
FI974321A0 (en) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multiple heparinglycosaminoglycans and proteoglycans are used
WO2000001406A1 (en) * 1998-07-07 2000-01-13 Welfide Corporation Medicinal utilization of heparin cofactor ii
WO2001005434A2 (en) * 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
DE10132307A1 (en) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Pharmaceutical preparation for inhalation of antithrombin in inflammatory lung diseases and ARDS
CA2480790A1 (en) * 2002-04-01 2003-10-16 Kazunori Murakami Use of antithrombin iii in treating acute lung injury
EP1603601A1 (en) * 2003-02-20 2005-12-14 Hamilton Civic Hospitals Research Development, Inc. Coating composition for polymeric surfaces comprising serpin or serpin derivatives
CA2535446A1 (en) * 2003-08-12 2005-02-17 Hamilton Civic Hospitals Research Development Inc. Methods for preventing neurological events
US7146034B2 (en) * 2003-12-09 2006-12-05 Superpower, Inc. Tape manufacturing system
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
DK1841458T3 (en) * 2005-01-06 2012-04-23 Discovery Lab Inc Surfactant treatment regimen to treat or prevent bronchopulmonary dysplasia
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (en) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 Pegylated factor viii
US11229746B2 (en) 2006-06-22 2022-01-25 Excelsior Medical Corporation Antiseptic cap
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
US9078992B2 (en) 2008-10-27 2015-07-14 Pursuit Vascular, Inc. Medical device for applying antimicrobial to proximal end of catheter
ES2797649T3 (en) 2011-07-12 2020-12-03 Icu Medical Inc Device for the delivery of antimicrobial agent in a transdermal catheter
JPWO2015005459A1 (en) * 2013-07-10 2017-03-02 生化学工業株式会社 Pharmaceutical composition for respiratory administration
US10196625B2 (en) 2013-09-30 2019-02-05 Seikagaku Corporation Method for improving blood persistence of protein
GB201415062D0 (en) 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
CA2960832A1 (en) * 2014-09-18 2016-03-24 Chondronest Sa Composition containing glycosaminoglycans and proteins
ES2828692T3 (en) * 2015-01-09 2021-05-27 Seikagaku Kogyo Co Ltd Chondroitinsulfuric acid derivative and drug to treat bladder diseases
WO2016182822A1 (en) 2015-05-08 2016-11-17 Icu Medical, Inc. Medical connectors configured to receive emitters of therapeutic agents
DK3525865T3 (en) 2016-10-14 2022-10-24 Icu Medical Inc Disinfectant caps for medical connectors
WO2018204206A2 (en) 2017-05-01 2018-11-08 Icu Medical, Inc. Medical fluid connectors and methods for providing additives in medical fluid lines
US11534595B2 (en) 2018-11-07 2022-12-27 Icu Medical, Inc. Device for delivering an antimicrobial composition into an infusion device
US11541220B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Needleless connector with antimicrobial properties
US11541221B2 (en) 2018-11-07 2023-01-03 Icu Medical, Inc. Tubing set with antimicrobial properties
US11517732B2 (en) 2018-11-07 2022-12-06 Icu Medical, Inc. Syringe with antimicrobial properties
US11400195B2 (en) 2018-11-07 2022-08-02 Icu Medical, Inc. Peritoneal dialysis transfer set with antimicrobial properties
EP3883638A1 (en) 2018-11-21 2021-09-29 ICU Medical, Inc. Antimicrobial device comprising a cap with ring and insert
EP4255552A1 (en) 2020-12-07 2023-10-11 ICU Medical, Inc. Peritoneal dialysis caps, systems and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3842061A (en) * 1971-09-08 1974-10-15 Kabi Ab Method for isolation of antithrombin from animal tissue materials by adsorption on sulfated carbohydrate gel
EP0098814A1 (en) * 1982-06-10 1984-01-18 KabiVitrum AB Antithrombin-heparin complex
EP0137356A2 (en) * 1983-09-26 1985-04-17 Miles Inc. Covalently bound heparin - antithrombin-III complex, method for its preparation and its use for treating thromboembolism
FR2635019A1 (en) * 1988-08-02 1990-02-09 Centre Nat Rech Scient MATERIAL CAPABLE OF FIXING BIOLOGICAL SUBSTANCES, AND ITS APPLICATIONS IN PARTICULAR AS SUPPORT FOR CHROMATOGRAPHY OF AFFINITY

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824092A (en) 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
US3616935A (en) 1970-02-05 1971-11-02 Dow Chemical Co Preparation of antithrombogenic surfaces
US3673612A (en) 1970-08-28 1972-07-04 Massachusetts Inst Technology Non-thrombogenic materials and methods for their preparation
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
JPS6040859B2 (en) 1977-07-27 1985-09-12 喜温 三浦 Antithrombotic artificial medical materials
JPS597693B2 (en) 1978-01-07 1984-02-20 株式会社ミドリ十字 Antithrombin preparation and its manufacturing method
FR2472390A1 (en) 1979-05-04 1981-07-03 Merieux Inst PROCESS FOR THE PREPARATION OF HIGHLY PURIFIED PROTHROMBINIC COMPLEX CONCENTRATES AND CONCENTRATES OBTAINED
CA1171375A (en) 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity
US4446126A (en) 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Antithrombin-heparin complex and method for its production
US4604762A (en) 1981-02-13 1986-08-12 Thoratec Laboratories Corporation Arterial graft prosthesis
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
NL188622C (en) 1981-12-15 1992-08-17 Cordis Europ METHOD TO IMPROVE THE BLOOD COMPATIBILITY OF A MATERIAL SURFACE BY COATING MATERIALS WITH HEPARIN OR HEPARIN-ANALOGUES AND PROTEIN FILM AND OBJECT, INCLUDING A SURFACE WITH IMPROVED BLOOD COMPATIBILITY OBTAINED BY APPLYING TO THE SURFACE MADE HEPARIN OR HEPARIN-ANALOGUES AND PROTEIN FILM.
SE8200751L (en) 1982-02-09 1983-08-10 Olle Larm PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS
US5002582A (en) 1982-09-29 1991-03-26 Bio-Metric Systems, Inc. Preparation of polymeric surfaces via covalently attaching polymers
AT379310B (en) 1983-05-20 1985-12-27 Immuno Ag METHOD FOR PRODUCING AN ANTITHROMBIN III-HEPARIN OR ANTITHROMBIN III HEPARINOID CONCENTRATE
DE3331009A1 (en) 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
US4448718A (en) * 1983-09-13 1984-05-15 Massachusetts Institute Of Technology Method for the preparation of collagen-glycosaminoglycan composite materials
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
DE3422494A1 (en) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen METHOD AND DEVICE FOR SPECIFIC ADSORPTION OF HEPARIN
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
CH665954A5 (en) 1985-07-08 1988-06-30 Battelle Memorial Institute SUBSTRATE WITH A SURFACE OF ANTITHROMBOGENIC ACTIVITY.
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
DE3636590A1 (en) 1986-10-28 1988-05-26 Braun Melsungen Ag BLOOD REPLACEMENT
DE3639561A1 (en) 1986-11-20 1988-06-01 Baumann Hanno METHOD FOR PRODUCING NON-THROMBOGEN SUBSTRATES
FR2614026B1 (en) * 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
NL8701337A (en) 1987-06-09 1989-01-02 Sentron V O F SUBSTRATE PROVIDED WITH A BLOOD COMPATIBLE SURFACE OBTAINED BY COUPLING WITH THE SURFACE OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH AN INHIBITORY INFLUENCE ON THE FORMATION OF BLOOD CLOTS AND / OR CONTAINED FROM HARMFOLIC CIRCULARS.
JP2739050B2 (en) 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 Anticoagulant
DE3806562A1 (en) 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh TWO CHAMBER SYRINGE WITH A FILLING OF ACTIVITY SENSITIVE HUMAN PROTEIN AS AN ACTIVE SUBSTANCE
FR2631970B1 (en) 1988-05-24 1993-12-24 Sanofi N-POLYOSYL-POLYPEPTIDES
DE3819079A1 (en) 1988-06-04 1989-12-07 Hoechst Ag HIRUDINE DERIVATIVES WITH DELAYED EFFECT
US5338770A (en) 1988-06-08 1994-08-16 Cardiopulmonics, Inc. Gas permeable thrombo-resistant coatings and methods of manufacture
US5182317A (en) 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5262451A (en) 1988-06-08 1993-11-16 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
CA1336396C (en) 1988-07-25 1995-07-25 Kiyoshi Kita Intraocular anticoagulant including antithrombin iii and method of administration
US5023078A (en) * 1988-08-10 1991-06-11 Albert P. Halluin Plasminogen activator-heparin conjugates
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
US5270046A (en) 1988-09-27 1993-12-14 Ube Industries, Ltd. Heparin bound anti-thrombotic material
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
NL194941C (en) 1990-02-15 2003-08-04 Cordis Corp Method for applying a physiologically active compound to a substrate surface.
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5275838A (en) 1990-02-28 1994-01-04 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
JP2975632B2 (en) 1990-03-30 1999-11-10 生化学工業株式会社 Glycosaminoglycan-modified protein
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5222971A (en) 1990-10-09 1993-06-29 Scimed Life Systems, Inc. Temporary stent and methods for use and manufacture
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5159050A (en) 1991-05-09 1992-10-27 Becton, Dickinson And Company Polyurethane and medical article therefrom
AT395596B (en) 1991-06-20 1993-01-25 Immuno Ag METHOD FOR PRODUCING ACTIVATED PROTEIN C
SG81873A1 (en) 1991-08-16 2001-07-24 Miles A Galin Medicament coated refractive anterior chamber ocular implant
SE470006B (en) 1991-09-26 1993-10-25 Corline Systems Ab New conjugate, its preparation and use, and substrates prepared with the conjugate
AU649885B2 (en) 1991-10-01 1994-06-02 Nisshinbo Industries, Inc. Antithrombotic resin, tube, film and coating
US5319072A (en) 1992-01-10 1994-06-07 Alpha Therapeutic Corporation Human antithrombin-III preparation
US5436291A (en) 1992-07-09 1995-07-25 University Of Michigan, The Board Of . . . Calcification-resistant synthetic biomaterials
EP0623150A4 (en) 1992-11-19 1999-08-25 Univ Case Western Reserve Nonthrombogenic implant surfaces.
JP3711561B2 (en) 1993-04-05 2005-11-02 三菱ウェルファーマ株式会社 Antithrombin-III liquid formulation and stabilization method thereof
EP0714412A1 (en) * 1993-08-19 1996-06-05 Minnesota Mining And Manufacturing Company Heparin functional affinity supports
IL110367A (en) 1994-07-19 2007-05-15 Colbar Lifescience Ltd Collagen-based matrix
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5876433A (en) 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5811151A (en) 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US5851229A (en) 1996-09-13 1998-12-22 Meadox Medicals, Inc. Bioresorbable sealants for porous vascular grafts
US5855618A (en) 1996-09-13 1999-01-05 Meadox Medicals, Inc. Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin
US5741881A (en) 1996-11-25 1998-04-21 Meadox Medicals, Inc. Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US5891196A (en) 1997-04-16 1999-04-06 Baxter International Inc. Method for actively binding heparin to crosslinked biological tissues
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US20010007063A1 (en) 1997-06-18 2001-07-05 Yoshihiro Oyama Antithrombotic medical material
US5945457A (en) 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US6024918A (en) 1998-03-13 2000-02-15 Medtronic, Inc. Method for attachment of biomolecules to surfaces of medical devices
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3842061A (en) * 1971-09-08 1974-10-15 Kabi Ab Method for isolation of antithrombin from animal tissue materials by adsorption on sulfated carbohydrate gel
EP0098814A1 (en) * 1982-06-10 1984-01-18 KabiVitrum AB Antithrombin-heparin complex
EP0137356A2 (en) * 1983-09-26 1985-04-17 Miles Inc. Covalently bound heparin - antithrombin-III complex, method for its preparation and its use for treating thromboembolism
US4689323A (en) * 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
FR2635019A1 (en) * 1988-08-02 1990-02-09 Centre Nat Rech Scient MATERIAL CAPABLE OF FIXING BIOLOGICAL SUBSTANCES, AND ITS APPLICATIONS IN PARTICULAR AS SUPPORT FOR CHROMATOGRAPHY OF AFFINITY

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 122, no. 25, 19 June 1995, Columbus, Ohio, US; abstract no. 306176, UNO, TAKEJI ET AL: "Evaluation for antithrombogenicity on the surface of heparinized biomedical material using thrombin-antithrombin III complex" XP002034214 *
HATTON, M. W. C. ET AL: "Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta", THROMB. RES. (1978), 13(4), 655-70 CODEN: THBRAA;ISSN: 0049-3848, 1978, XP000676774 *
M.M. MAIMONE ET AL.: "STRUCTURE OF A DERMATAN SULFATE HEXASACCHARIDE THAT BINDS TO HEPARIN COFACTOR II WITH HIGH AFFINTY.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 30, 25 October 1990 (1990-10-25), MD US, pages 18263 - 18271, XP002034213 *
SEITAI ZAIRYO (1995), 13(1), 21-5 CODEN: SEZAEH;ISSN: 0910-304X, 1995 *
VERSTRAETE M.: "PREVENTION OF THROMBOSIS IN ARTERIES: NOVEL APPROACHES.", J. CARDIOVASC. PHARMACOL., vol. 7, no. SUPPL.3, 1985, pages S191 - S205, XP000676772 *

Also Published As

Publication number Publication date
EP0863768B1 (en) 2007-01-03
EP0863768A2 (en) 1998-09-16
JP2000501082A (en) 2000-02-02
CA2237159C (en) 2010-11-16
DE69636813D1 (en) 2007-02-15
WO1997019701A2 (en) 1997-06-05
CA2237159A1 (en) 1997-06-05
US20030100487A1 (en) 2003-05-29
JP4166275B2 (en) 2008-10-15
ATE350066T1 (en) 2007-01-15
US6562781B1 (en) 2003-05-13
AU7688396A (en) 1997-06-19
DE69636813T2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
WO1997019701A3 (en) Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
Marcum et al. Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells
PT1319183E (en) Methods and products related to low molecular weight heparin
NO860940L (en) PROCEDURE FOR THE PREPARATION OF NATURAL HEPARINE SULPHATE AND DERMATAN SULPHATE IN PRINCIPLE PURE FORM.
CA2253833A1 (en) Derivatives of k5 polysaccharide having high anticoagulant activity
DK0450628T3 (en) Saccharide-mediated, water-soluble proteins
ATE92313T1 (en) N-ACETYLGLUCOSAMINE AS A CYTOPROTECTIVE AGENT.
CA2154080A1 (en) Novel anticoagulant cofactor activity
EP0333243A3 (en) Sulphated k5 antigen and sulphated k5 antigen fragments
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
EP0345248A3 (en) Use of the enzyme-cofactor nadph in the preparation of a pharmaceutical, pharmaceutical and preparation thereof
AU3927189A (en) N-2,3-butadienyl tri- and tetraaminoalkane derivatives
Clements et al. Human α‐l‐iduronidase: 2. Catalytic properties
Bengtsson et al. Interaction of heparin with proteins Demonstration of different binding sites for antithrombin and lipoprotein lipase
AU2001246510A1 (en) Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
Jordan et al. Stereoelectronic factors in the binding of substrate analogs and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes
Murata et al. High-performance liquid chromatographic identification of eight constitutional disaccharides from heparan sulfate isomers digested with heparitinases
Marcum et al. Anticoagulantly active heparin-like molecules from cultured fibroblasts
KR930700549A (en) Novel megakaryocyte colony stimulating factor and its manufacturing method
WO2001036462A3 (en) Protein c derivatives
Taniguchi et al. Diagnosis of genetic mucopolysaccharidoses: electrophoretic and enzymatic characterization of urinary glycosaminoglycans
Murata et al. High-performance liquid chromatographic identification of disaccharides generated from heparan sulphate isomers using heparitinases
Kindness et al. The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III.
DE69427232D1 (en) METHOD FOR PRODUCING DISACCHARIDES AND SACCHARIDES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2237159

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2237159

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1997 520033

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996939779

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996939779

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1996939779

Country of ref document: EP